179 related articles for article (PubMed ID: 22875025)
1. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice.
Wong KK; Brenneman F; Chesney A; Spaner DE; Gorczynski RM
Cancer Res; 2012 Oct; 72(19):4931-43. PubMed ID: 22875025
[TBL] [Abstract][Full Text] [Related]
2. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.
Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y
Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.
Gorczynski RM; Chen Z; Diao J; Khatri I; Wong K; Yu K; Behnke J
Breast Cancer Res Treat; 2010 Sep; 123(2):405-15. PubMed ID: 19953316
[TBL] [Abstract][Full Text] [Related]
4. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.
Dürig J; Ebeling P; Grabellus F; Sorg UR; Möllmann M; Schütt P; Göthert J; Sellmann L; Seeber S; Flasshove M; Dührsen U; Moritz T
Cancer Res; 2007 Sep; 67(18):8653-61. PubMed ID: 17875705
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
7. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.
Aydin S; Grabellus F; Eisele L; Möllmann M; Hanoun M; Ebeling P; Moritz T; Carpinteiro A; Nückel H; Sak A; Göthert JR; Dührsen U; Dürig J
Eur J Haematol; 2011 Jul; 87(1):10-9. PubMed ID: 21692849
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
10. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
[TBL] [Abstract][Full Text] [Related]
11. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
12. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
[TBL] [Abstract][Full Text] [Related]
13. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies.
Hummel JL; Lichty BD; Reis M; Dubé I; Kamel-Reid S
Leukemia; 1996 Aug; 10(8):1370-6. PubMed ID: 8709647
[TBL] [Abstract][Full Text] [Related]
14. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.
Prieto A; Garcia-Suarez J; Reyes E; Lapeña P; Hernandez M; Alvarez-Mon M
Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression.
Moga E; Cantó E; Vidal S; Juarez C; Sierra J; Briones J
Exp Hematol; 2011 Nov; 39(11):1064-71. PubMed ID: 21864486
[TBL] [Abstract][Full Text] [Related]
16. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
17. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rγnull mice is attributed to a lack of CD11c+B220+CD122+ cells.
Ito R; Katano I; Ida-Tanaka M; Kamisako T; Kawai K; Suemizu H; Aiso S; Ito M
J Immunol; 2012 Nov; 189(9):4313-20. PubMed ID: 23018460
[TBL] [Abstract][Full Text] [Related]
18. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
19. Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice.
O'Brien S; Jeha S; Kantarjian H; Pisa P; Jin G; Keating M; Beran M
Leukemia; 1996 Feb; 10(2):338-44. PubMed ID: 8637244
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
